Turoctocog alfa pegol

Pre-clinicalRecruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Haemophilia A

Conditions

Haemophilia A

Trial Timeline

Dec 9, 2020 → Feb 1, 2026

NCT ID

NCT04682145

About Turoctocog alfa pegol

Turoctocog alfa pegol is a pre-clinical stage product being developed by Novo Nordisk for Haemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04682145. Target conditions include Haemophilia A.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04334057	Pre-clinical	Completed	Mar 31, 2021	Jan 10, 2024	Haemophilia A
NCT04682145	Pre-clinical	Recruiting	Dec 9, 2020	Feb 1, 2026	Haemophilia A
NCT02994407	Phase 1	Completed	Jan 30, 2017	Oct 15, 2018	Congenital Bleeding Disorder
NCT02920398	Phase 1	Completed	Oct 4, 2016	Apr 7, 2017	Congenital Bleeding Disorder
NCT02137850	Phase 3	Completed	Jun 26, 2014	Jun 7, 2023	Congenital Bleeding Disorder
NCT01731600	Phase 3	Completed	Feb 20, 2013	Sep 28, 2018	Congenital Bleeding Disorder
NCT01489111	Phase 3	Completed	Aug 3, 2012	Dec 10, 2018	Congenital Bleeding Disorder
NCT01480180	Phase 3	Completed	Jan 30, 2012	Dec 10, 2018	Congenital Bleeding Disorder

Competing Products

20 competing products in Haemophilia A

See all competitors

Product	Company	Stage	Hype Score
Mim8	Novo Nordisk	Phase 3	76
Turoctocog alfa	Novo Nordisk	Phase 3	76
NNC0365-3769 (Mim8)	Novo Nordisk	Phase 3	76
Turoctocog alfa pegol	Novo Nordisk	Pre-clinical	22
Mim8 B, 10 mg/mL + Mim8 B, 100 mg/mL + Mim8 B, placebo	Novo Nordisk	Phase 1	32
Concizumab	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Phase 3	76
turoctocog alfa pegol (N8-GP)	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Phase 3	76
Esperoct	Novo Nordisk	Pre-clinical	22
NNC0442-0344 A	Novo Nordisk	Phase 1	32
NNC0365-3769 (Mim8) PPX	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Pre-clinical	22
Refixia®	Novo Nordisk	Pre-clinical	22
NNC0442-0344 A + Placebo	Novo Nordisk	Phase 1	32
Mim8	Novo Nordisk	Phase 3	76
Turoctocog alfa pegol (N8-GP)	Novo Nordisk	Pre-clinical	22
Nonacog beta pegol	Novo Nordisk	Pre-clinical	22
Concizumab	Novo Nordisk	Pre-clinical	22
Turoctocog alfa	Novo Nordisk	Pre-clinical	22

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved